Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nystatin,Triamcinolone Acetonide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Aleor Dermaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Alembic Pharmaceuticals' JV Gets USFDA Final Nod for Anti-Fungal Drug
Details : The approved ANDA is therapeutically equivalent to the reference-listed drug product Nystatin and Triamcinolone Acetonide ointment, of strength 100,000 units/gram, used for the treatment of cutaneous candidiasis.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 08, 2022
Lead Product(s) : Nystatin,Triamcinolone Acetonide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Aleor Dermaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nystatin,Triamcinolone Acetonide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1 mg/gram, of Taro Pharmaceuticals U.S.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 01, 2021
Lead Product(s) : Nystatin,Triamcinolone Acetonide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?